Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
- Development stage
- Preclinical
- Lead developer
- Amgen
- Modality
- Small Molecules
- Administration
- Oral (investigational/preclinical)
01
Overview
This compound is a synthetic small molecule belonging to the phenylpyrazole class. It was developed as a potent and selective inhibitor of p38α mitogen‑activated protein kinase (MAPK14), an enzyme involved in inflammatory signaling pathways. The compound exhibits low nanomolar inhibitory activity against p38α MAPK and has been shown to suppress TNFα production in preclinical models. It was investigated for its potential as an anti-inflammatory agent but has not advanced beyond preclinical or early-phase development.[1][6]
- Other names
- N-cyclopropyl-3-(1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-ylamino)-4-methylbenzamideN-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-[...]-pyrazolo[3,4-b]pyridin[...]amino}-4-methylbenzamide (various IUPAC and synonym forms)[2][7]
02
Targets
MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide.